Many individuals with type 2 diabetes (T2D) cannot take current therapies due to their adverse effects.
Thus, new glucose-lowering agents targeting unique mechanisms are needed.
Studies have demonstrated that decreasing ketone oxidation, secondary to muscle-specific deletion of succinyl-CoA:3-ketoacid-CoA transferase (SCOT), protects mice against obesity-related hyperglycemia.
